Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Scandinavian ChemoTech AB (publ)
  6. News
  7. Summary
    CMOTEC B   SE0009242654

SCANDINAVIAN CHEMOTECH AB (PUBL)

(CMOTEC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Scandinavian ChemoTech : has been invited to participate in two prestigious events

08/25/2020 | 05:01am EDT

Scandinavian ChemoTech has been invited to participate in both the Life Science Intelligence "LSI" Emerging Medtech Summit in California and the EU Gateway - Business Avenues in Singapore and Indonesia.

LSI Emerging Medtech Summit is an event that brings together the best strategists, investors and innovators in the Med Tech industry. The summit will take place at the Ritz - Carlton in Laguna Niguel California on February 17 - 20, 2021 and is a 3-day event where ChemoTech and other medical technology companies will present their innovations to some of the largest medical technology players and institutional investors. ChemoTech was also invited to the event in 2020 but could unfortunately not participate.

The company has also been selected for an EU-led export delegation to Singapore and Indonesia, which is largely funded by the EU. The delegation takes place in connection with one of Asia's largest medical technology fairs 9 - 11 December 2020, which takes place in Singapore. After Singapore, the delegation will continue to a medical technology fair in Jakarta, Indonesia, with the opportunity to continue to showcase the company's products to doctors, veterinarians and industry stakeholders, as well as to establish contacts with strategic partners.

"We feel honoured to have been selected to present our company and patented technology at these prestigious events. We look forward to reaching a wider audience with our tumour specific electroporation and making new business contacts for both veterinary and human medicine. We are of course prepared that these events, due to prevailing pandemic, may be cancelled or postponed. "- says Mohan Frick, CEO

For further information please contact:

Mohan Frick, Co-Founder and CEO

+46 (0)10-218 93 00

info@chemotech.se

 

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: info@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.

https://news.cision.com/chemotech/r/scandinavian-chemotech-has-been-invited-to-participate-in-two-prestigious-events,c3180691

https://mb.cision.com/Main/14967/3180691/1296951.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about SCANDINAVIAN CHEMOTECH AB (PUBL)
09/06SCANDINAVIAN CHEMOTECH AB : is carrying out another directed new share issue and will rece..
AQ
09/03SCANDINAVIAN CHEMOTECH : subsidiary Vetiqure AB begins its marketing in the US
AQ
09/03SCANDINAVIAN CHEMOTECH : is carrying out a directed new share issue and will receive appro..
AQ
08/25SCANDINAVIAN CHEMOTECH AB : (publ) Interim report Q1 January - June 2021 - Executive Summa..
AQ
08/17Scandinavian Chemotech AB Publ Reports Earnings Results for the Second Quarter Ended Ju..
CI
07/16SCANDINAVIAN CHEMOTECH : Board member buys additional shares in Scandinavian ChemoTech AB
AQ
07/08SCANDINAVIAN CHEMOTECH : starts a feasibility study ináthe USA
AQ
07/08Scandinavian ChemoTech Starts Feasibility Study in the USA
CI
06/17SCANDINAVIAN CHEMOTECH : receives approval from the European Patent Office
AQ
06/17Scandinavian ChemoTech Receives Approval from the European Patent Office
CI
More news
Financials
Sales 2021 - - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 188 M 21,8 M 21,8 M
Capi. / Sales 2021 -
Capi. / Sales 2022 40,0x
Nbr of Employees 7
Free-Float 56,5%
Chart SCANDINAVIAN CHEMOTECH AB (PUBL)
Duration : Period :
Scandinavian ChemoTech AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 21,80 SEK
Average target price 21,50 SEK
Spread / Average Target -1,38%
Managers and Directors
Stefan Mohan Frick Chief Executive Officer & Director
Lars Olof Hedbys Chairman
Urban Hňkan WidÚn Chief Operating Officer
Bengt Georg Gustaf Engstr÷m Director
Rolf Bertil Ehrnstr÷m Director
Sector and Competitors